A Phase I, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics and Efficacy of the XZB-0004 in Patients With Solid Tumours
Latest Information Update: 31 Oct 2024
At a glance
- Drugs SLC 391 (Primary) ; Pembrolizumab
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 28 Oct 2024 Status changed from not yet recruiting to recruiting.
- 20 Mar 2023 New trial record